Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective
- PMID: 22035254
- DOI: 10.1146/annurev-pharmtox-010611-134623
Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective
Abstract
Intravenously injected nanoparticulate drug carriers provide a wide range of unique opportunities for site-specific targeting of therapeutic agents to many areas within the vasculature and beyond. Pharmacokinetics and biodistribution of these carriers are controlled by a complex array of interrelated core and interfacial physicochemical and biological factors. Pertinent to realizing therapeutic goals, definitive maps that establish the interdependency of nanoparticle size, shape, and surface characteristics in relation to interfacial forces, biodistribution, controlled drug release, excretion, and adverse effects must be outlined. These concepts are critically evaluated and an integrated perspective is provided on the basis of the recent application of nanoscience approaches to nanocarrier design and engineering. The future of this exciting field is bright; some regulatory-approved products are already on the market and many are in late-phase clinical trials. With concomitant advances in extensive computational knowledge of the genomics and epigenomics of interindividual variations in drug responses, the boundaries toward development of personalized nanomedicines can be pushed further.
Similar articles
-
Pharmacokinetics and biodistribution of nanoparticles.Mol Pharm. 2008 Jul-Aug;5(4):496-504. doi: 10.1021/mp800049w. Epub 2008 Jul 9. Mol Pharm. 2008. PMID: 18611037 Review.
-
More effective nanomedicines through particle design.Small. 2011 Jul 18;7(14):1919-31. doi: 10.1002/smll.201100442. Epub 2011 Jun 22. Small. 2011. PMID: 21695781 Free PMC article. Review.
-
Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.Nanomedicine (Lond). 2018 Mar 1;13(5):539-554. doi: 10.2217/nnm-2017-0338. Epub 2018 Jan 30. Nanomedicine (Lond). 2018. PMID: 29381129
-
Surface modification and local orientations of surface molecules in nanotherapeutics.J Control Release. 2015 Jun 10;207:131-42. doi: 10.1016/j.jconrel.2015.04.017. Epub 2015 Apr 14. J Control Release. 2015. PMID: 25883030 Review.
-
Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.Pharmacol Ther. 2010 Nov;128(2):324-35. doi: 10.1016/j.pharmthera.2010.07.007. Epub 2010 Aug 10. Pharmacol Ther. 2010. PMID: 20705093 Review.
Cited by
-
In vitro activity of Paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells.Biomacromolecules. 2013 Jun 10;14(6):2074-82. doi: 10.1021/bm400434h. Epub 2013 May 9. Biomacromolecules. 2013. PMID: 23617223 Free PMC article.
-
Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats.Mol Pharm. 2013 May 6;10(5):1977-87. doi: 10.1021/mp4000019. Epub 2013 Apr 22. Mol Pharm. 2013. PMID: 23534919 Free PMC article.
-
Microporation-Mediated Transdermal Delivery of In Situ Gel Incorporating Etodolac-Loaded PLGA Nanoparticles for Management of Rheumatoid Arthritis.Pharmaceutics. 2024 Jun 21;16(7):844. doi: 10.3390/pharmaceutics16070844. Pharmaceutics. 2024. PMID: 39065541 Free PMC article.
-
Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.Int J Mol Sci. 2021 May 17;22(10):5264. doi: 10.3390/ijms22105264. Int J Mol Sci. 2021. PMID: 34067699 Free PMC article. Review.
-
Endocytosis Controls siRNA Efficiency: Implications for siRNA Delivery Vehicle Design and Cell-Specific Targeting.Nucleic Acid Ther. 2020 Feb;30(1):22-32. doi: 10.1089/nat.2019.0804. Epub 2019 Nov 12. Nucleic Acid Ther. 2020. PMID: 31718426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
